ArticlePloS one2026
Protodioscin mitigates cyclophosphamide-induced renal toxicity in HEK-293 cells by regulating endoplasmic reticulum stress, antioxidant defense, and apoptotic pathways.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclophosphamide (CTX) is a widely used chemotherapeutic agent with well-established efficacy; however, its clinical use is limited by dose-dependent adverse effects, particularly nephrotoxicity. Protodioscin (Prot), a bioactive saponin derived from plants of the Dioscoreaceae family, has demonstrated notable antioxidant and anti-inflammatory properties. This study aimed to evaluate the protective effects of Prot against CTX-induced cytotoxicity in HEK-293 cells. Primary HEK-293 kidney cells were exposed to the IC50 concentration of CTX in the presence or absence of Prot (5 and 10 µM) for 24 hours. Cell viability was assessed using the MTT assay. Gene expression of Bax and Bcl-2 was measured by real-time PCR assay, while protein expression of Bax, cleaved caspase-3, Bcl-2, ATF6, PERK, GRP78, CHOP, p-eIF2α, p-PERK, and cleaved ATF6 were evaluated by Western blot analysis. Oxidative stress parameters, including CAT, SOD, GPx, GSH, MDA, and NO, were quantified using spectrophotometric assays, and kidney injury markers (KIM-1 and cystatin C) were measured by ELISA. Prot decreased Bax and caspase 3 expression and increased Bcl-2 expression in HEK-293 cells exposed to CTX, which was accompanied by reduced apoptosis. Treatment with 5 and 10 µM Prot significantly reduced the expression of ATF6, PERK, GRP78, CHOP, p-eIF2α, p-PERK and Cleaved- ATF6 proteins in CTX-exposed HEK-293 cells. Additionally, treatment with Prot significantly increased catalase, GPx, GSH, and SOD levels, while reducing KIM-1, cystatin C, MDA, and NO levels in HEK-293 cells subjected to CTX. These findings suggest that Prot exerts a protective role against CTX-induced renal injury in HEK-293 cells by modulating apoptotic pathways, attenuating endoplasmic reticulum stress, and improving antioxidant indices.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.